EGFR and cancer: Most abundantly predicted compounds include anti-cancer drugs targeting tubulin polymerization, MAPK signaling, and EGFR signaling, as well as current lupus standard-of-care therapies, including corticosteroids and prostaglandin synthesis inhibitors.